NCT00381680 · OUTCOME

Gene Expression Profile

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia · Source last updated 2024-03-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 36 months

What was measured

Percent of unfavorable gene expression profile of early versus late marrow relapse.

Analysis population: The data were not collected due to the lack of funds.

Groups in this outcome

Regimen A: Standard Vincristine Dosing

Standard VCR dosing (1.5 mg/m\^2, max 2 mg)

Arm B: Randomized High Dose Vincristine Regimen

Intensive VCR dosing (2 mg/m\^2, max 2.5 mg)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Regimen A: Standard Vincristine Dosing	0
Arm B: Randomized High Dose Vincristine Regimen	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
0
units
Participants

description

Percent of unfavorable gene expression profile of early versus late marrow relapse.

groups

description
Standard VCR dosing (1.5 mg/m\^2, max 2 mg)
id
OG000
title
Regimen A: Standard Vincristine Dosing
description
Intensive VCR dosing (2 mg/m\^2, max 2.5 mg)
id
OG001
title
Arm B: Randomized High Dose Vincristine Regimen

population Description

The data were not collected due to the lack of funds.

reporting Status

POSTED

time Frame

Up to 36 months

title

Gene Expression Profile

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice